AACE Rare Diseases and Hormone Disorders Webinar Series is pleased to present When Triglycerides Skyrocket: Recognizing and Treating Severe Hypertriglyceridemia. This course is designed to help clinicians create a path to diagnosis when encountering a patient with severe hypertriglyceridemia (SHTG).
This disease was chosen due to its rarity, symptom complexity, and need for improved diagnostic and management strategies. The on-demand webinar will provide clinicians with the latest evidence-based clinical guidance and educational resources for diagnosing, managing, and treating SHTG. By highlighting the latest research and clinical advances, AACE aims to increase clinicians’ awareness, knowledge, and competence, ultimately improving the quality of care and outcomes for patients with this rare endocrine disease.
Upon completion of the program, participants will be able to:
1. Describe the diagnostic and testing approach in evaluating a patient with severe hypertriglyceridemia.
2. Utilize evidence-based guidelines, algorithms, and consensus statements to diagnose and treat severe hypertriglyceridemia.
3. Identify and treat long-term complications and comorbidities of severe hypertriglyceridemia.
Robert H. Eckel, MD
Professor of Medicine, Emeritus
Division of Endocrinology, Metabolism & Diabetes
Division of Cardiology
S/P Professor of Physiology & Biophysics
S/P Charles A. Boettcher II Chair in Atherosclerosis
University of Colorado Anschutz Medical Campus
Past President, North American Association for the Study of Obesity (AKA The Obesity Society)
Past President, American Heart Association
Past President Medicine and Science, American Diabetes Association
The Kidney in Cardiometabolic Disease session presented at the AACE 2025 Annual Meeting highlights the critical role of kidney function in managing cardiometabolic disorders, such as diabetes, heart failure, and cardiovascular diseases, emphasizing the importance of integrated care approaches through a case-based interactive program format.
The session aims to deepen understanding of how renal dysfunction can influence the progression and management of cardiometabolic diseases, with an emphasis on:
• The pathophysiology of chronic kidney disease within the cardiometabolic spectrum, including age-related changes and mineral-bone disorders.• The impact of renal impairment on cardiovascular risk and metabolic control.• Strategies for early detection and management of renal complications in cardiometabolic patients, including risk assessment considerations for aging populations with declining renal function